Phase IIb trial of TG 4001 (tipapkinogene sovacivec) in patients with HPV16-positive oropharyngeal squamous cell carcinomas.

Trial Profile

Phase IIb trial of TG 4001 (tipapkinogene sovacivec) in patients with HPV16-positive oropharyngeal squamous cell carcinomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs Tipapkinogene sovacivec (Primary) ; Antineoplastics
  • Indications Human papillomavirus infections; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 24 Mar 2015 Status changed from planning to discontinued, based on a Transgene media release.
    • 21 Nov 2012 New trial record
    • 13 Nov 2012 First safety and efficacy results are expected to be available in 2016, according to a Transgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top